Research programme: therapeutic agents - Kuhnil Pharmaceutical

Drug Profile

Research programme: therapeutic agents - Kuhnil Pharmaceutical

Alternative Names: K-0803; KI 1002; KI 1003; KI 1103; KI 1104; KI 1105; KI-0802; KI-0804; KI-0902; KI-0904; KI-0905; KI-0906; KI-0907; KI-1007; KT 1101

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Kuhnil Pharmaceutical Company
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alopecia
  • Research Angina pectoris; Cancer; Eating disorders; Genitourinary disorders; Musculoskeletal disorders
  • Discontinued Arthritis; Asthma; Gastrointestinal ulcer; Obesity

Most Recent Events

  • 19 Jul 2016 Early research in Musculoskeletal disorders in South Korea (unspecified route) before July 2016
  • 19 Jul 2016 Early research in Genitourinary disorders in South Korea (unspecified route) before July 2016
  • 19 Jul 2016 Preclinical trials in Alopecia in South Korea (unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top